View ValuationMedPacto 将来の成長Future 基準チェック /06現在、 MedPactoの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長21.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Jun 03Forecast to breakeven in 2022The analyst covering MedPacto expects the company to break even for the first time. New forecast suggests the company will make a profit of ₩46.0b in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule.すべての更新を表示Recent updates分析記事 • May 16MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • May 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩148.2b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩3.9b revenue, or US$2.6m). Market cap is less than US$100m (₩148.2b market cap, or US$99.2m).お知らせ • Mar 07MedPacto, Inc., Annual General Meeting, Mar 26, 2026MedPacto, Inc., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 104, myeongdal-ro, seocho-gu, seoul South Korea分析記事 • Jan 30Companies Like MedPacto (KOSDAQ:235980) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Nov 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue is less than US$1m (₩1.3b revenue, or US$872k).分析記事 • Oct 18MedPacto (KOSDAQ:235980) Is In A Strong Position To Grow Its BusinessEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Oct 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.2b (US$97.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩1.3b revenue, or US$885k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (₩140.2b market cap, or US$97.7m).New Risk • Sep 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩1.3b revenue, or US$912k). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change).分析記事 • Jul 05We're Not Worried About MedPacto's (KOSDAQ:235980) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Mar 22We Think MedPacto (KOSDAQ:235980) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Mar 15MedPacto, Inc., Annual General Meeting, Mar 28, 2025MedPacto, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 104, myeongdal-ro, seocho-gu, seoul South KoreaNew Risk • Jan 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (2.1% increase in shares outstanding).New Risk • Dec 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.5b (US$94.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₩135.5b market cap, or US$94.6m).分析記事 • Nov 18Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding).分析記事 • Aug 05Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Mar 28MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Dec 28New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 59% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Revenue is less than US$1m.New Risk • Nov 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩28b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩28b free cash flow). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Jun 03Forecast to breakeven in 2022The analyst covering MedPacto expects the company to break even for the first time. New forecast suggests the company will make a profit of ₩46.0b in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule.Is New 90 Day High Low • Feb 18New 90-day low: ₩77,200The company is down 26% from its price of ₩104,100 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.Is New 90 Day High Low • Jan 18New 90-day low: ₩87,600The company is down 26% from its price of ₩118,500 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.分析記事 • Jan 05We Think MedPacto (KOSDAQ:235980) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. Indeed, MedPacto... このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、MedPacto は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A235980 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20264,785-13,212-13,178-12,921N/A12/31/20253,898-12,811-13,633-13,390N/A9/30/20252,469-14,571-14,054-13,655N/A6/30/20251,270-11,805-11,097-10,689N/A3/31/2025430-14,220-12,279-11,905N/A12/31/2024N/A-20,140-16,882-16,559N/A9/30/2024N/A-23,306-21,246-21,053N/A6/30/2024N/A-27,751-25,224-25,097N/A3/31/2024N/A-30,632-27,804-27,654N/A12/31/2023N/A-35,325-26,474-26,301N/A9/30/2023N/A-42,452-28,335-28,259N/A6/30/2023N/A-44,620-29,528-28,935N/A3/31/2023N/A-45,069-28,189-27,468N/A12/31/2022N/A-35,753-30,539-29,614N/A9/30/2022N/A-28,514-27,679-26,508N/A6/30/2022N/A-26,742-26,328-25,480N/A3/31/2022N/A-20,476-29,359-28,575N/A12/31/2021N/A-17,040-26,062-25,153N/A9/30/2021N/A-17,558-25,414-24,515N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A235980の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A235980の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A235980の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A235980の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A235980の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A235980の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/15 16:14終値2026/07/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MedPacto, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Taehee KimMirae Asset Securities Co., Ltd.Eun Jung SongNomura Securities Co. Ltd.
Breakeven Date Change • Jun 03Forecast to breakeven in 2022The analyst covering MedPacto expects the company to break even for the first time. New forecast suggests the company will make a profit of ₩46.0b in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
分析記事 • May 16MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • May 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩148.2b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩3.9b revenue, or US$2.6m). Market cap is less than US$100m (₩148.2b market cap, or US$99.2m).
お知らせ • Mar 07MedPacto, Inc., Annual General Meeting, Mar 26, 2026MedPacto, Inc., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 104, myeongdal-ro, seocho-gu, seoul South Korea
分析記事 • Jan 30Companies Like MedPacto (KOSDAQ:235980) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Nov 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue is less than US$1m (₩1.3b revenue, or US$872k).
分析記事 • Oct 18MedPacto (KOSDAQ:235980) Is In A Strong Position To Grow Its BusinessEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Oct 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.2b (US$97.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩1.3b revenue, or US$885k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (₩140.2b market cap, or US$97.7m).
New Risk • Sep 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩1.3b revenue, or US$912k). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change).
分析記事 • Jul 05We're Not Worried About MedPacto's (KOSDAQ:235980) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Mar 22We Think MedPacto (KOSDAQ:235980) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Mar 15MedPacto, Inc., Annual General Meeting, Mar 28, 2025MedPacto, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 104, myeongdal-ro, seocho-gu, seoul South Korea
New Risk • Jan 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (2.1% increase in shares outstanding).
New Risk • Dec 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.5b (US$94.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₩135.5b market cap, or US$94.6m).
分析記事 • Nov 18Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding).
分析記事 • Aug 05Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Mar 28MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Dec 28New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 59% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Revenue is less than US$1m.
New Risk • Nov 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩28b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩28b free cash flow). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Jun 03Forecast to breakeven in 2022The analyst covering MedPacto expects the company to break even for the first time. New forecast suggests the company will make a profit of ₩46.0b in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
Is New 90 Day High Low • Feb 18New 90-day low: ₩77,200The company is down 26% from its price of ₩104,100 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Jan 18New 90-day low: ₩87,600The company is down 26% from its price of ₩118,500 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.
分析記事 • Jan 05We Think MedPacto (KOSDAQ:235980) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. Indeed, MedPacto...